155 related articles for article (PubMed ID: 32449435)
1. Burkitt lymphoma-related
Yamazaki T; Liu L; Conlon EG; Manley JL
RNA Biol; 2020 Oct; 17(10):1383-1390. PubMed ID: 32449435
[TBL] [Abstract][Full Text] [Related]
2. TCF3 mutually exclusive alternative splicing is controlled by long-range cooperative actions between hnRNPH1 and PTBP1.
Yamazaki T; Liu L; Manley JL
RNA; 2019 Nov; 25(11):1497-1508. PubMed ID: 31391218
[TBL] [Abstract][Full Text] [Related]
3. TCF3 alternative splicing controlled by hnRNP H/F regulates E-cadherin expression and hESC pluripotency.
Yamazaki T; Liu L; Lazarev D; Al-Zain A; Fomin V; Yeung PL; Chambers SM; Lu CW; Studer L; Manley JL
Genes Dev; 2018 Sep; 32(17-18):1161-1174. PubMed ID: 30115631
[TBL] [Abstract][Full Text] [Related]
4. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.
Schmitz R; Young RM; Ceribelli M; Jhavar S; Xiao W; Zhang M; Wright G; Shaffer AL; Hodson DJ; Buras E; Liu X; Powell J; Yang Y; Xu W; Zhao H; Kohlhammer H; Rosenwald A; Kluin P; Müller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Ogwang MD; Reynolds SJ; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Pittaluga S; Wilson W; Waldmann TA; Rowe M; Mbulaiteye SM; Rickinson AB; Staudt LM
Nature; 2012 Oct; 490(7418):116-20. PubMed ID: 22885699
[TBL] [Abstract][Full Text] [Related]
5. Transcription factor 3 (TCF3) combined with histone deacetylase 3 (HDAC3) down-regulates microRNA-101 to promote Burkitt lymphoma cell proliferation and inhibit apoptosis.
Dong L; Huang J; Zu P; Liu J; Gao X; Du J; Li Y
Bioengineered; 2021 Dec; 12(1):7995-8005. PubMed ID: 34658308
[TBL] [Abstract][Full Text] [Related]
6. Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the non-Hodgkin Lymphoma Berlin-Frankfurt-Münster protocols.
Rohde M; Bonn BR; Zimmermann M; Lange J; Möricke A; Klapper W; Oschlies I; Szczepanowski M; Nagel I; Schrappe M; ; ; Loeffler M; Siebert R; Reiter A; Burkhardt B
Haematologica; 2017 Jun; 102(6):1091-1098. PubMed ID: 28209658
[TBL] [Abstract][Full Text] [Related]
7. SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma.
Wilke AC; Doebele C; Zindel A; Lee KS; Rieke SA; Ceribelli M; Comoglio F; Phelan JD; Wang JQ; Pikman Y; Jahn D; Häupl B; Schneider C; Scheich S; Tosto FA; Bohnenberger H; Stauder P; Schnütgen F; Slabicki M; Coulibaly ZA; Wolf S; Bojarczuk K; Chapuy B; Brandts CH; Stroebel P; Lewis CA; Engelke M; Xu X; Kim H; Dang TH; Schmitz R; Hodson DJ; Stegmaier K; Urlaub H; Serve H; Schmitt CA; Kreuz F; Knittel G; Rabinowitz JD; Reinhardt HC; Vander Heiden MG; Thomas C; Staudt LM; Zenz T; Oellerich T
Blood; 2022 Jan; 139(4):538-553. PubMed ID: 34624079
[TBL] [Abstract][Full Text] [Related]
8. Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma.
López C; Kleinheinz K; Aukema SM; Rohde M; Bernhart SH; Hübschmann D; Wagener R; Toprak UH; Raimondi F; Kreuz M; Waszak SM; Huang Z; Sieverling L; Paramasivam N; Seufert J; Sungalee S; Russell RB; Bausinger J; Kretzmer H; Ammerpohl O; Bergmann AK; Binder H; Borkhardt A; Brors B; Claviez A; Doose G; Feuerbach L; Haake A; Hansmann ML; Hoell J; Hummel M; Korbel JO; Lawerenz C; Lenze D; Radlwimmer B; Richter J; Rosenstiel P; Rosenwald A; Schilhabel MB; Stein H; Stilgenbauer S; Stadler PF; Szczepanowski M; Weniger MA; Zapatka M; Eils R; Lichter P; Loeffler M; Möller P; Trümper L; Klapper W; ; Hoffmann S; Küppers R; Burkhardt B; Schlesner M; Siebert R
Nat Commun; 2019 Mar; 10(1):1459. PubMed ID: 30926794
[TBL] [Abstract][Full Text] [Related]
9. Sporadic and endemic Burkitt lymphoma have frequent
Zhou P; Blain AE; Newman AM; Zaka M; Chagaluka G; Adlar FR; Offor UT; Broadbent C; Chaytor L; Whitehead A; Hall A; O'Connor H; Van Noorden S; Lampert I; Bailey S; Molyneux E; Bacon CM; Bomken S; Rand V
Blood Adv; 2019 Jul; 3(14):2118-2127. PubMed ID: 31300419
[TBL] [Abstract][Full Text] [Related]
10. The PCBP1 gene encoding poly(rC) binding protein I is recurrently mutated in Burkitt lymphoma.
Wagener R; Aukema SM; Schlesner M; Haake A; Burkhardt B; Claviez A; Drexler HG; Hummel M; Kreuz M; Loeffler M; Rosolowski M; López C; Möller P; Richter J; Rohde M; Betts MJ; Russell RB; Bernhart SH; Hoffmann S; Rosenstiel P; Schilhabel M; Szczepanowski M; Trümper L; Klapper W; Siebert R; ;
Genes Chromosomes Cancer; 2015 Sep; 54(9):555-64. PubMed ID: 26173642
[TBL] [Abstract][Full Text] [Related]
11. Identification and functional analysis of porcine basic helix-loop-helix transcriptional factor 3 (TCF3) and its alternative splicing isoforms.
Yang F; Wang N; Liu Y; Wang H
Res Vet Sci; 2016 Apr; 105():1-4. PubMed ID: 27033898
[TBL] [Abstract][Full Text] [Related]
12. [Expression of TCF3 in Burkitt's Lymphoma and Its Proliferative Effect and Prognostic Significance].
Dong LH; Huang JJ; Liu J; Gao X; DU JW; Li YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1435-1439. PubMed ID: 36208246
[TBL] [Abstract][Full Text] [Related]
13. The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma.
Wagener R; Seufert J; Raimondi F; Bens S; Kleinheinz K; Nagel I; Altmüller J; Thiele H; Hübschmann D; Kohler CW; Nürnberg P; Au-Yeung R; Burkhardt B; Horn H; Leoncini L; Jaffe ES; Ott G; Rymkiewicz G; Schlesner M; Russell RB; Klapper W; Siebert R
Blood; 2019 Feb; 133(9):962-966. PubMed ID: 30567752
[TBL] [Abstract][Full Text] [Related]
14. Update on Burkitt Lymphoma.
Dunleavy K; Little RF; Wilson WH
Hematol Oncol Clin North Am; 2016 Dec; 30(6):1333-1343. PubMed ID: 27888884
[TBL] [Abstract][Full Text] [Related]
15. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
Kleo K; Dimitrova L; Oker E; Tomaszewski N; Berg E; Taruttis F; Engelmann JC; Schwarzfischer P; Reinders J; Spang R; Gronwald W; Oefner PJ; Hummel M
BMC Cancer; 2019 Apr; 19(1):322. PubMed ID: 30953469
[TBL] [Abstract][Full Text] [Related]
16. Uncoupling between Ig somatic hypermutation and oncogene mutation in mouse lymphoma.
Vincent C; Truffinet V; Fiancette R; Petit B; Cogné N; Cogné M; Denizot Y
Biochim Biophys Acta; 2009 Feb; 1793(2):418-26. PubMed ID: 19026697
[TBL] [Abstract][Full Text] [Related]
17. Deep sequencing of MYC DNA-binding sites in Burkitt lymphoma.
Seitz V; Butzhammer P; Hirsch B; Hecht J; Gütgemann I; Ehlers A; Lenze D; Oker E; Sommerfeld A; von der Wall E; König C; Zinser C; Spang R; Hummel M
PLoS One; 2011; 6(11):e26837. PubMed ID: 22102868
[TBL] [Abstract][Full Text] [Related]
18. A recurrent clonally distinct Burkitt lymphoma case highlights genetic key events contributing to oncogenesis.
Penther D; Viailly PJ; Latour S; Etancelin P; Bohers E; Vellemans H; Camus V; Menard AL; Coutant S; Lanic H; Lemasle E; Drieux F; Veresezan L; Ruminy P; Raimbault A; Soulier J; Frebourg T; Tilly H; Jardin F
Genes Chromosomes Cancer; 2019 Aug; 58(8):595-601. PubMed ID: 30779244
[TBL] [Abstract][Full Text] [Related]
19. Clonality Analysis of Immunoglobulin Gene Rearrangement by Next-Generation Sequencing in Endemic Burkitt Lymphoma Suggests Antigen Drive Activation of BCR as Opposed to Sporadic Burkitt Lymphoma.
Amato T; Abate F; Piccaluga P; Iacono M; Fallerini C; Renieri A; De Falco G; Ambrosio MR; Mourmouras V; Ogwang M; Calbi V; Rabadan R; Hummel M; Pileri S; Leoncini L; Bellan C
Am J Clin Pathol; 2016 Jan; 145(1):116-27. PubMed ID: 26712879
[TBL] [Abstract][Full Text] [Related]
20. Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets.
Bouska A; Bi C; Lone W; Zhang W; Kedwaii A; Heavican T; Lachel CM; Yu J; Ferro R; Eldorghamy N; Greiner TC; Vose J; Weisenburger DD; Gascoyne RD; Rosenwald A; Ott G; Campo E; Rimsza LM; Jaffe ES; Braziel RM; Siebert R; Miles RR; Dave S; Reddy A; Delabie J; Staudt LM; Song JY; McKeithan TW; Fu K; Green M; Chan WC; Iqbal J
Blood; 2017 Oct; 130(16):1819-1831. PubMed ID: 28801451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
